Trial Profile
Multicenter, Pivotal Phase III Study of Iodine-131 Anti-B1 Antibody (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Iodine-131 tositumomab (Primary) ; Tositumomab
- Indications B-cell lymphoma; Lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 12 Oct 2009 New trial record